PFE — Pfizer, Inc. Common Stock
Session close: $28.47. Regular-session share volume: 24,595,503. Change from previous close: -1.35%.
Key developments
Pfizer closed its acquisition of Metsera, marking a re-entry into the obesity drug market focused on injectables. The deal gives Pfizer control of Metsera's portfolio of long-acting obesity drug candidates targeting chronic weight management, and management plans to use those programs to compete in the crowded anti-obesity segment. The article notes investors should weigh the acquisition against the company's wider risks.
Company news Pfizer (PFE) Re Enters Obesity Drugs With Metsera Acquisition
A market report on drug and gene delivery devices lists Pfizer among the companies cited as accelerating next-generation delivery platforms, a sector-level reference rather than a company-specific development.
News sources
Company news Drug and Gene Delivery Devices - Global Strategic Business Report 2026: Capitalize on 8.1% CAGR to Secure the $1.2 Billion Market by 2032 as AbbVie, Moderna, Pfizer and Novartis Accelerate · Company news Pfizer (PFE) Re Enters Obesity Drugs With Metsera Acquisition